RELAZIONE CLINICA SULL'IMPIEGO DI UN NUOVO ANTIMICOTICO PER USO TOPICO

After some remarks about the pathogenetic epidemiological aspects of dermatomycosis, the authors report the results obtained in a clinical study performed to evaluate the therapeutic efficacy of clotrimazole (Canesten), a new antimycotic for topical use. Altogether, 31 male patients and 19 female patients were treated, suffering from the following diseases: pityriasis versicolor (13 cases), vulvo vaginal and perineal candidiasis (3 cases), palmar and plantar mycosis (10), inguinal epidermophytosis (7 cases), onychomycosis (2), trichophytosis (12) and other mycoses (3). Canesten was employed, depending upon the localization of the infection, in the form of lotion, cream or both preparations. The average time of treatment ranged from 15.2 to 72 days, as a function of the type of mycosis. Concerning the therapeutic evaluations, Canesten enabled the obtainment, in 84% of cases, of the remission of symptoms and the negativization of the laboratory findings within exceptionally short times ('excellent' results) and within average times ('good' results). The fast working solution is particularly stressed in the treatment of pityriasis and candidiasis. The therapeutic outcome was unsatisfactory in only 3 patients. The critical evaluation of the results confirms, therefore, the very high tolerance and the remarkable therapeutic activity of Canesten.